Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey

Boehringer Ingelheim among top ten most “patient-centric” pharma companies*

“PatientView” announced results from its annual international survey among patient groups. In the category “worked with”, where patient organizations who have collaborated with pharmaceutical companies in 2019 rated the performance of the companies, Boehringer Ingelheim entered the top ten and is now ranked on place nine climbing from rank 14th in 20181.

The survey was conducted between November 19, 2019 and February 20, 2020 among 1,850 patient groups from 95 countries covering 124 medical specialties. Due to the timing, COVID-19 should have little impact on the results of the study but the indicators are even more important these days. Patient groups assessed 48 different pharmaceutical companies across twelve indicators including patient centricity, safety, high product quality, transparency, integrity, quality of relationship, engaging patient in research and development which resulted in two separate summary scores one for companies they are “familiar with” and one for companies they have “worked with”. In both categories, being “familiar with” and having “worked with,” Boehringer Ingelheim’s ranking continuously improved since 2015.

Also across all twelve indicators Boehringer Ingelheim scored positively in the top tier of pharmaceutical companies and ranked fourth in “engaging patients in research” among patient groups that had “worked with” Boehringer Ingelheim. 

“Over the past years, Boehringer Ingelheim has focused on developing long-term collaborations with patient organizations. We are immensely grateful for the patient community’s interest and valuable advice.” said Henrik Finnern, Head of Global Patient Advocacy Relations: “The positive perception by patient organizations is a huge motivation for colleagues across Boehringer Ingelheim and recognizes their daily efforts to meet patient needs and expectations. Especially during this difficult time with COVID-19 affecting our lives we are continuing to support the patient community and it is our greatest wish that everyone is staying healthy.”

PatientView is a UK-based research, publishing and consultancy firm that gives voice to patient organizations. The company has published its annual Reputation Report since 2011. Patient organizations from various disease and healthcare sectors are surveyed. The report help to define what patients expect from pharmaceutical companies.

About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life. 

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at or in our annual report:

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Boehringer Ingelheim is committed to the global community and to the well-being of people and animals. As a research-driven company, it started its support activities in January and will continue to do what it can to deliver a meaningful contribution in the fight against COVID-19. The company continues to support healthcare systems by reliably supplying drugs and through our research.

More information on the various COVID-19 initiatives and topics are available under:

Intended audiences
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Article and photo source: